Using Rig-I–/– tumor–bearing mouse models, we were the first to demonstrate that intrinsic RIG-I antagonizes CD8+ T cell survival and effector function in the TME and undermines CD8+ T cell-mediated antitumor immunity (Figures 1 and 2). This evidence concerns the gene CD8A and neoplasm.